Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12626001050347p
Ethics application status
Submitted, not yet approved
Date submitted
5/08/2026
Date registered
26/08/2026
Date last updated
26/08/2026
Date data sharing statement initially provided
26/08/2026
Type of registration
Prospectively registered
Titles & IDs
Public title
A study in healthy volunteers to compare how much SOR102 gets into the blood and how much passes out in the stool when taken as a capsule or as a tablet, and when taken with food
Query!
Scientific title
A Multiple-Dose, Open-Label, Sequential, Formulation Comparability Bridging Study to Compare the Serum Levels and Fecal Recovery of a Capsule and Tablet Formulation of SOR102 and to Assess the Serum Levels and Fecal Recovery of SOR102 Dosed Under Nonfasted Conditions in Healthy Volunteers
Query!
Additional trial identifiers [1]
318083
0
SOR102-103
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Inflammatory bowel disease
343108
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
339200
339200
0
0
Query!
Inflammatory bowel disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Approximately 16 healthy men or women will be enrolled in this study. There will be three periods in the study study.
- Period 1: In Period 1, participants will receive the SOR102 capsule formulation at a dose of 675mg given orally twice a day under fasted conditions for 7 days, Participants will receive their morning and evening dose of SOR102 following a fast of at least 2 hours and will be required to continue to fast from food for a minimum of 1 hour following administration of SOR102 . With the exception of the 240 mL of water taken with the dose, participants will not be allowed fluids from 2 hours prior to until 1 hour after dosing. Following completion of 7 days of SOR102 dosing, participants will be discharged from the Clinical Research Unit on Day 8 for the first 7 day washout period.
- Period 2: Following the washout period, participants will return to the Clinical Research Unit for Period 2 where they will receive the SOR102 tablet formulation at a dose of 600mg given orally twice a day under fasted conditions for 7 days. Participants will receive their morning and evening dose of SOR102 following a fast of at least 2 hours and will be required to continue to fast from food for a minimum of 1 hour following administration of SOR102 . With the exception of the 240 mL of water taken with the dose, participants will not be allowed fluids from 2 hours prior to until 1 hour after dosing. Following completion of 7 days of SOR102 dosing, participants will be discharged from the Clinical Research Unit on Day 8 for the second 7 day washout period.
- Period 3: Following the washout period, participants will return to the Clinical Research Unit for Period 3 where they will receive the SOR102 tablet formulation at a dose of 600mg given orally twice a day under nonfasted conditions for 7 days. Each dose of SOR102 will be taken 15 minutes after completion of a standard non-high fat meal. The meal will have about 45 to 65 grams of carbohydrates, 25 to 40 grams of protein, and 10 to 15 grams of fat. Following completion of 7 days of SOR102 dosing, participants will be discharged from the Clinical Research Unit on Day 8. Participants will return to the Clinical Research Unit for an ambulatory follow-up visit 1 week later.
Query!
Intervention code [1]
334967
0
Treatment: Drugs
Query!
Description of the comparator or control
No control group
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
346440
0
Serum levels of SOR102 capsules taken fasted orally BID in healthy adult participants over the course of 7 days.
Query!
Assessment method [1]
346440
0
Serum concentrations of SOR102 measured using a validated bioanalytical method
Query!
Timepoint [1]
346440
0
Blood will be collected pre-dose on Day 1 and on Day 8 (post first dose) prior to discharge.
Query!
Primary outcome [2]
346441
0
Fecal recovery of SOR102 capsules taken fasted orally BID in healthy adult participants over the course of 7 days.
Query!
Assessment method [2]
346441
0
Fecal concentrations of SOR102 measured using a validated bioanalytical method
Query!
Timepoint [2]
346441
0
In each period, all stools will be collected from the time of admission to the Clinical Research Unit through discharge on Day 8 (post the first dose for the period)
Query!
Primary outcome [3]
346558
0
Fecal recovery of SOR102 tablets taken fasted orally BID in healthy adult participants over the course of 7 days.
Query!
Assessment method [3]
346558
0
Fecal concentrations of SOR102 measured using a validated bioanalytical method
Query!
Timepoint [3]
346558
0
All stools will be collected from the time of admission to the Clinical Research Unit through discharge on Day 8 (post the first dose for the period)
Query!
Secondary outcome [1]
465850
0
Assess the composite safety and tolerability of SOR102 in healthy adult participants.
Query!
Assessment method [1]
465850
0
Regular solicitation of adverse events by asking nonleading questions such as "how do you feel", review of physical examination data, blood pressure measured using a sphygmomanometer, tympanic temperature measured by inserting a specialized infrared ear thermometer into the ear canal, pulse rate measured using a manual pulse count ECG measurements using a digital ECG monitor to collect heart rate, PR interval, RR interval, QRS interval and QT interval, review of clinical laboratory values from blood and urine. Adverse events will be graded as mild, moderate or severe using standard definitions provided in the protocol where mild is transient and may require only minimal treatment or therapeutic intervention, moderate is an adverse event that is usually alleviated with additional specific therapeutic intervention and severe is an adverse event that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention
Query!
Timepoint [1]
465850
0
Treatment-emergent adverse events will be collected from the time of signing the informed consent form through the follow-up visit. Physical examinations will be performed at screening and at the follow-up visit with symptom directed physical examinations performed at Day -1, Day 4 and Day 8 (post first dose) in each Period, Vital signs will be collected at screening, in each Period once daily on Day -1 through Day 8 (post first dose) in each period, and at the follow-up visit (Day 43 post the Period 1 first dose). ECGs will be collected at screening and at the follow-up visit (Day 43 post the Period 1 first dose). Clinical laboratory assessments of blood and urine will be collected at screening, on Day -1 and Day 8 (post first dose) in Period 1, on Day -1, Day 4 and Day 8 (post first dose) in Period 2 and Period 3, and at the follow-up visit (Day 43 post the Period 1 first dose).
Query!
Secondary outcome [2]
466378
0
Primary outcome: Serum levels of SOR102 tablets taken fasted orally BID in healthy adult participants over the course of 7 days.
Query!
Assessment method [2]
466378
0
Serum concentrations of SOR102 measured using a validated bioanalytical method
Query!
Timepoint [2]
466378
0
Blood will be collected pre-dose on Day 1 and on Day 8 (post first dose) prior to discharge.
Query!
Secondary outcome [3]
466379
0
Primary outcome: Serum levels of SOR102 tablets taken nonfasted orally BID in healthy adult participants over the course of 7 days.
Query!
Assessment method [3]
466379
0
Serum concentrations of SOR102 measured using a validated bioanalytical method
Query!
Timepoint [3]
466379
0
Blood will be collected pre-dose on Day 1 and on Day 8 (post first dose) prior to discharge. A final sample will be collected at the Follow-Up visit (Day 43 post the Period 1 first dose).
Query!
Secondary outcome [4]
466380
0
Primary outcome: Fecal recovery of SOR102 tablets taken nonfasted orally BID in healthy adult participants over the course of 7 days.
Query!
Assessment method [4]
466380
0
Fecal concentrations of SOR102 measured using a validated bioanalytical method
Query!
Timepoint [4]
466380
0
All stools will be collected from the time of admission to the Clinical Research Unit through discharge on Day 8 (post the first dose for the period)
Query!
Eligibility
Key inclusion criteria
Body weight at least 50kg and no more than 110kg and body mass index within the range 18-35 kg/m2 (inclusive)
Deemed healthy as determined by medical history, physical examination, vital sign measurements, ECG, and laboratory safety tests
No clinically relevant abnormalities in clinical laboratory evaluations
Normal bowel habits
Not lactating or pregnant
Capable of giving signed informed consent
Agrees to be available for all study visits and cooperates fully with the requirements of the study protocol, including the schedule of assessments
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
Yes
Query!
Key exclusion criteria
Clinically relevant history of physical or mental health abnormalities that might interfere with the study
Clinically relevant abnormal laboratory results, 12-lead ECG and vital signs, or physical findings
History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the study drug.
History of latent or active tuberculosis.
Positive (or 2 indeterminate) QuantiFERON test results.
Positive test for hepatitis B surface antigen, anti-hepatitis C antibody or human immunodeficiency virus I and II.
Positive urine test for drugs of abuse or alcohol breath test
Taken part in a clinical study and has received a medication or a new chemical entity within 30 days or 5 half-lives (whichever is longer) prior to dosing of current study medication.
Use or intended use of any prohibited medications
Known history of heart disease.
History of significant GI disease, including GI motility disorders.
History of abnormal bowel habits (e.g., a history of chronic constipation or chronic diarrhea).
Previous surgery to the GI tract with the exception of appendectomy and hernia repair
Systolic BP (SBP) of 160 mmHg or diastolic BP (DBP) of 95 mmHg
Orthostatic intolerance at Screening
Participant is unlikely to co-operate with the requirements of the study, in the opinion of the Investigator.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
9/11/2026
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
16/11/2026
Query!
Actual
Query!
Date of last data collection
Anticipated
29/12/2026
Query!
Actual
Query!
Sample size
Target
16
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Recruitment hospital [1]
29949
0
CMAX Clinical Research Pty Ltd - Adelaide
Query!
Recruitment postcode(s) [1]
46312
0
5000 - Adelaide
Query!
Funding & Sponsors
Funding source category [1]
322642
0
Commercial sector/Industry
Query!
Name [1]
322642
0
Sorriso Pharmaceuticals Australia, Pty. Ltd
Query!
Address [1]
322642
0
Query!
Country [1]
322642
0
Australia
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sorriso Pharmaceuticals Australia, Pty. Ltd
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
325567
0
None
Query!
Name [1]
325567
0
Query!
Address [1]
325567
0
Query!
Country [1]
325567
0
Query!
Ethics approval
Ethics application status
Submitted, not yet approved
Query!
Ethics committee name [1]
321100
0
Bellberry Human Research Ethics Committee G
Query!
Ethics committee address [1]
321100
0
https://bellberry.com.au/
Query!
Ethics committee country [1]
321100
0
Australia
Query!
Date submitted for ethics approval [1]
321100
0
04/08/2026
Query!
Approval date [1]
321100
0
Query!
Ethics approval number [1]
321100
0
Query!
Summary
Brief summary
This study will compare how much SOR102 is found in the blood and stool and look at the safety of both a tablet and capsule dose formulation of SOR102. The capsule formulation has been tested in healthy volunteers before, with the tablet formulation being given for the first time in humans in this study. SOR102 is being developed as a potential treatment for inflammatory bowel disease. You may be eligible for this study if you are a healthy adult man or woman aged between 18 and 65 years old.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
152666
0
Dr Jessica Gehlert
Query!
Address
152666
0
CMAX Clinical Research Pty Ltd, Ground Floor, 21-24 North Terrace, Adelaide, South Australia 5000
Query!
Country
152666
0
Australia
Query!
Phone
152666
0
+61 0421311443
Query!
Fax
152666
0
Query!
Email
152666
0
[email protected]
Query!
Contact person for public queries
Name
152667
0
CMAX Clinical Research Pty Ltd
Query!
Address
152667
0
CMAX Clinical Research Pty Ltd, Ground Floor, 21-24 North Terrace, Adelaide, South Australia 5000
Query!
Country
152667
0
Australia
Query!
Phone
152667
0
+61 8 7088 7900
Query!
Fax
152667
0
Query!
Email
152667
0
[email protected]
Query!
Contact person for scientific queries
Name
152668
0
CMAX Clinical Research Pty Ltd
Query!
Address
152668
0
CMAX Clinical Research Pty Ltd, Ground Floor, 21-24 North Terrace, Adelaide, South Australia 5000
Query!
Country
152668
0
Australia
Query!
Phone
152668
0
+61 8 7088 7900
Query!
Fax
152668
0
Query!
Email
152668
0
[email protected]
Query!
Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment:
Only aggregate participant data will be available from this study
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF